Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Kraslavas Aprinkis, Latvia Clinical Trials

A listing of Kraslavas Aprinkis, Latvia clinical trials actively recruiting patients volunteers.

RESULTS

Found (2280) clinical trials

Modulation of Gut Microbiota by Rifaximin in PD Patients

Gut microbiota is the largest microorganisms pool in the human body. The physiological roles of gut microbiota for digestion, metabolism, immune homeostasis, GI-tract infection prevention and anti-inflammation. The very first colonized gut microbiota of infant are from maternal vaginal fluid. Gut microbiota are strongly affected by the environment, diet and ...

Phase

Evaluation the Effects of Pycnogenol Supplementation on the Clinical Status in Traumatic Brain Injury Patients

Randomization investigators randomly assign eligible patients on enrolment (1:1) to either the control group or the intervention group. Randomization is stratified by site and a randomization list of unique patient identifiers is generated by the study statistician using a computer-generated random block size. The classification is based on age (18 ...

Phase

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

This proposed study will be the first to test nivolumab in combination with AZA in pediatric patients with hematologic malignancies. Patients will receive the first dose of nivolumab on day 1 along with AZA. After "chemotherapy priming", a second dose of nivolumab will be given at day 15 which will ...

Phase

Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL

This is a combined Phase 1/2 study of oral TP-0903 in patients with previously treated CLL/SLL. In both Phase 1 and Phase 2, study participants will be assigned to one of two defined patient groups: Group 1 (TP-0903 monotherapy): Patients with CLL/SLL who are intolerant to, or have progressed on, ...

Phase

Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

In phase I of the trial, the investigators aim to explore the safety and feasibility of abemaciclib in combination with nivolumab in patients with recurrent/metatstatic head and neck squamous cell carcinoma (RM-HNSCC). A dose de-escalation study design will be used to determine the recommended phase II dose (RP2D) of abemaciclib ...

Phase

UCDCC#272: IL-2 Radiotherapy and Pembrolizumab in Patients Refractory to Checkpoint Blockade

This is a phase I/II study that will evaluate the safety and toxicity of this combinatorial approach. Eligible patients >18 years of age with histologically proven metastatic NSCLC, melanoma, RCC, or HNSCC who have failed PD-1 / PD-L1 checkpoint blockade therapy will be enrolled. Patients must have a candidate treatment ...

Phase

Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma

Angiosarcoma is a rare and aggressive form of soft tissue sarcoma. Prior work demonstrates very poor outcomes, with most patients developing metastatic disease and less than 50% surviving greater than 5 years. In other soft tissue sarcomas, the use of radiotherapy and/or chemotherapy have improved progression-free survival in patients undergoing ...

Phase

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

Phase I: The purpose of the first phase of the study is to find the highest dose of CFI-402257 that can be tolerated without causing very severe side effects when receiving paclitaxel. This is done by starting at a dose lower than the one that is tolerated in patients when ...

Phase

A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

This study includes 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion). In phase 1, patients will be enrolled using a rolling 6 dose escalation scheme. The starting dose of LOXO-292 is equivalent to the adult recommended phase 2 dose of 160mg BID. Once the MTD and/or RP2D ...

Phase

Comparation Analgesia Efficiency With Sulfentanyl and Sevoflurane

Recently study found sevoflurane plays an important role through spinal nerve peptide receptor (NK.1R), glycine receptor (GlyR), neuron nicotinic receptor (nnAChRs), Methyl-1-methyl-1-day aspartate (NMDA receptor), and TRPV1 receptor (TRPV1 receptor) produce the analgesic efficiency. Sufentanyl was traditional opioid analgesic reagent. index of Nociception (NOX) was the objective index for analgesia ...

Phase